Novo Nordisk wins EU approval for Wegovy oral obesity pill

PUBT · 1d ago
Novo Nordisk wins EU approval for Wegovy oral obesity pill
  • Novo Nordisk secured European Commission marketing authorization for Wegovy pill, a once-daily oral semaglutide 25 mg for adult weight management.
  • The EU also cleared a single-dose pen version of the higher-dose Wegovy 7.2 mg injection for obesity.
  • Novo Nordisk cited OASIS 4 trial data showing about 17% mean weight loss for the pill versus 3% for placebo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607151150OMX_____CNEWS_EN_GNW1001212936_en) on July 15, 2026, and is solely responsible for the information contained therein.